Post-covid Henoch-schonlein Purpura: A Pediatric Case Report
Nadia Mebrouk *
Pédiatrie IV de l’Hôpital d’Enfants, Rabat Children's Hospital , CHU Ibn Sina, Rabat, Morocco.
Boutaina Halimi
Pédiatrie IV de l’Hôpital d’Enfants, Rabat Children's Hospital , CHU Ibn Sina, Rabat, Morocco.
Najlae El Attari
Pédiatrie IV de l’Hôpital d’Enfants, Rabat Children's Hospital , CHU Ibn Sina, Rabat, Morocco.
Youssra Abdeljalil
Pédiatrie IV de l’Hôpital d’Enfants, Rabat Children's Hospital , CHU Ibn Sina, Rabat, Morocco.
Chtouki Loubna
Pédiatrie IV de l’Hôpital d’Enfants, Rabat Children's Hospital , CHU Ibn Sina, Rabat, Morocco.
Abdelali Bentahila
Pédiatrie IV de l’Hôpital d’Enfants, Rabat Children's Hospital , CHU Ibn Sina, Rabat, Morocco.
*Author to whom correspondence should be addressed.
Abstract
We report the case of a 28-month-old boy who displayed symptoms of Henoch-Schonlein purpura (HSP), a type of small-vessel vasculitis that affects multiple systems in childhood and is caused by IgA. The symptoms include dermatological, abdominal, articular, and renal manifestations. HSP can occur due to several factors, such as upper respiratory tract infections, medications, vaccinations, and malignancies. The patient had positive COVID-19 serology but no other trigger factor for HSP, indicating a possible correlation between the two. The boy received oral prednisolone, leading to a swift clinical improvement. Our findings align with other research that suggests a link between the SARS-CoV-2 coronavirus and infantile HSP.
Keywords: COVID-19, henoch-schonleinpurpura, pediatric